Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.38 |
| ▸ | MMP1 | P03956 | 2/20 | 0.38 |
| ▸ | MMP9 | P14780 | 2/20 | 0.38 |
| ▸ | MMP3 | P08254 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20734875 | 1.00 | ALDH1A1 (0.41) | ALDH1A1MAPTHTTSMN1; SMN2NPC1 | |
| SCHEMBL20734824 | 0.91 | KMT2A (0.43) | ALDH1A1HTTSMN1; SMN2NPC1POLB | |
| SCHEMBL20734825 | 0.91 | KMT2A (0.43) | ALDH1A1HTTSMN1; SMN2NPC1POLB | |
| SCHEMBL24333180 | 0.89 | HTT (0.41) | ALDH1A1MAPTHTTSMN1; SMN2NPC1 | |
| SCHEMBL20734910 | 0.86 | MMP1 (0.48) | HTTSMN1; SMN2NPC1POLBRAB9A | |
| SCHEMBL20734861 | 0.85 | FFAR1 (0.44) | ALDH1A1MAPTHTTFFAR1KMT2A | |
| SCHEMBL20734860 | 0.85 | FFAR1 (0.44) | ALDH1A1MAPTHTTFFAR1KMT2A | |
| SCHEMBL20734938 | 0.83 | SMN1; SMN2 (0.37) | ALDH1A1HTTSMN1; SMN2POLBLMNA | |
| SCHEMBL20735040 | 0.83 | SMN1; SMN2 (0.37) | ALDH1A1HTTSMN1; SMN2POLBLMNA | |
| SCHEMBL20734814 | 0.83 | HPGD (0.40) | ALDH1A1MAPTHTTSMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11332440-B2 | 4-oxo-alkylated tetramic acid compound, and preparation method thereof | BEIJING JOEKAI BIOTECH. LLC (CN) | 2022-05-17 | — | — | US | disclosed |
| US-11130733-B2 | 4-OXO-alkylated tetramic acid compound, preparation method and use thereof | BEIJING JOEKAI BIOTECH. LLC (CN) | 2021-09-28 | — | — | US | disclosed |
| US-20200361868-A1 | 4-OXO-ALKYLATED TETRAMIC ACID COMPOUND, PREPARATION METHOD AND USE THEREOF | BEIJING JOEKAI BIOTECH. LLC (CN) | 2020-11-19 | — | — | US | disclosed |
| US-20200181081-A1 | 4-OXO-ALKYLATED TETRAMIC ACID COMPOUND, AND PREPARATION METHOD THEREOF | BEIJING JOEKAI BIOTECH. LLC (CN) | 2020-06-11 | — | — | US | disclosed |
| EP-3647306-A1 | 4-OXO-ALKYLATED TETRAMIC ACID COMPOUND AND PREPARATION METHOD THEREFOR | Beijing Joekai Biotech. LLC (CN) | 2020-05-06 | — | — | EP | disclosed |
| EP-3643311-A1 | 4-OXO-ALKYLATED TETRAMIC ACID COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | Beijing Joekai Biotech. LLC (CN) | 2020-04-29 | — | — | EP | disclosed |
| WO-2019029273-A1 | 4-OXO-ALKYLATED TETRAMIC ACID COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | 北京卓凯生物技术有限公司 | 2019-02-14 | — | — | WO | disclosed |
| WO-2019029274-A1 | 4-OXO-ALKYLATED TETRAMIC ACID COMPOUND AND PREPARATION METHOD THEREFOR | 北京卓凯生物技术有限公司 | 2019-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11130733-B2 | 4-OXO-alkylated tetramic acid compound, preparation method and use thereof | HTT, PARK7, PSEN1 | ALDH1A1 1056/4885MAPT 78/4885HTT 1/4885 |
| US-11332440-B2 | 4-oxo-alkylated tetramic acid compound, and preparation method thereof | PSEN1, PSEN2, APP | ALDH1A1 747/4885MAPT 34/4885HTT 110/4885 |
| US-20200181081-A1 | 4-OXO-ALKYLATED TETRAMIC ACID COMPOUND, AND PREPARATION METHOD THEREOF | PSEN1, PSEN2, APP | ALDH1A1 747/4885MAPT 34/4885HTT 110/4885 |
| US-20200361868-A1 | 4-OXO-ALKYLATED TETRAMIC ACID COMPOUND, PREPARATION METHOD AND USE THEREOF | HTT, PARK7, PSEN1 | ALDH1A1 1056/4885MAPT 78/4885HTT 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.